# Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Study · id `cardio:ct-nct04012775` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04012775](<https://clinicaltrials.gov/study/NCT04012775>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04012775

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

## Technical summary

Registry record NCT04012775. Randomized; no masking; primary purpose treatment. Start 2017-04-20 (actual); primary completion 2018-09-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT04012775, source copy `cardio:ctgov-nct04012775-2019-07-09`, retrieved 2026-10-26)
- Started: 2017-04-20 (actual) (ClinicalTrials.gov record NCT04012775, source copy `cardio:ctgov-nct04012775-2019-07-09`, retrieved 2026-10-26)
- Primary completion: 2018-09-24 (actual) (ClinicalTrials.gov record NCT04012775, source copy `cardio:ctgov-nct04012775-2019-07-09`, retrieved 2026-10-26)
- Completion: 2018-09-24 (actual) (ClinicalTrials.gov record NCT04012775, source copy `cardio:ctgov-nct04012775-2019-07-09`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT04012775, source copy `cardio:ctgov-nct04012775-2019-07-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04012775-2019-07-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Biological): Insulin Humulin® NPH
- Intervention (Biological): Insulin Rinsulin® NPH
- Lead sponsor: Geropharm
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Geropharm (`cardio:org-geropharm`)

## Provenance

Content hash: c072c282136eddd8b88674fe7347b847966cbbbc77bdf2fc0bafe6c4a89421aa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
